Q3 Earnings Estimate for REGENXBIO Issued By Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at Leerink Partnrs lowered their Q3 2025 EPS estimates for REGENXBIO in a research note issued to investors on Monday, September 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($1.31) for the quarter, down from their previous estimate of ($1.30). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s Q4 2025 earnings at $0.30 EPS, FY2025 earnings at ($2.27) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($1.25) EPS and FY2029 earnings at ($1.15) EPS.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.25). The firm had revenue of $21.36 million during the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%.

A number of other brokerages have also weighed in on RGNX. Barclays cut their target price on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Wall Street Zen lowered shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a report on Saturday, August 9th. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a report on Monday, September 8th. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of REGENXBIO in a report on Monday, September 8th. Finally, Royal Bank Of Canada cut their price target on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and an average price target of $28.38.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $9.03 on Wednesday. REGENXBIO has a fifty-two week low of $5.03 and a fifty-two week high of $13.15. The firm has a market capitalization of $456.11 million, a P/E ratio of -2.62 and a beta of 1.17. The company’s 50 day moving average price is $8.77 and its two-hundred day moving average price is $8.31.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors have recently added to or reduced their stakes in the company. Pale Fire Capital SE lifted its stake in REGENXBIO by 7.7% in the 2nd quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 2,000 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in REGENXBIO by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 2,326 shares in the last quarter. ProShare Advisors LLC lifted its stake in REGENXBIO by 22.4% in the 4th quarter. ProShare Advisors LLC now owns 15,314 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 2,800 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in REGENXBIO by 2.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,452 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 2,827 shares in the last quarter. Finally, Brooklyn Investment Group lifted its stake in REGENXBIO by 163.7% in the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 3,466 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

Insider Activity at REGENXBIO

In other news, CEO Curran Simpson sold 7,734 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $10.02, for a total transaction of $77,494.68. Following the completion of the sale, the chief executive officer directly owned 244,597 shares of the company’s stock, valued at $2,450,861.94. The trade was a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 12.79% of the stock is currently owned by insiders.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.